+ Resolve Article
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter

+ Translate
+ Subscribe to Site Feed
GeoScience Most Shared ContentMost Shared Content

Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist

, : Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist. European Journal of Pharmacology 590(1-3): 224-232

Treatment of obesity is still a large unmet medical need. Neuropeptide Y is the most potent orexigenic peptide in the animal kingdom. Its five cloned G-protein couple receptors are all implicated in the regulation of energy homeostasis evidenced by overexpression or deletion of neuropeptide Y or its receptors. Neuropeptide Y most likely exerts its orexigenic activity via the neuropeptide Y1 and neuropeptide Y5 receptors, although the involvement of the neuropeptide Y2 and neuropeptide Y4 receptors are also gaining importance. The lack of potent, selective, and brain penetrable pharmacologic agents at these receptors made our understanding of the modulation of food intake by neuropeptide Y-ergic agents elusive. BMS-193885 (1,4-dihydro-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino] carbonyl]amino]phenyl]-2,6-dimethyl-3,5-pyridinedicarboxylic acid, dimethyl ester) is a potent and selective neuropeptide Y1 receptor antagonist. BMS-193885 has 3.3 nM affinity at the neuropeptide Y1 receptor, acting competitively at the neuropeptide Y binding site. BMS-193885 increased the Kd of [125I]PeptideYY from 0.35 nM to 0.65 nM without changing the Bmax (0.16 pmol/mg of protein) in SK-N-MC cells that endogenously express the neuropeptide Y1 receptor. It is also found to be a full antagonist with an apparent Kb of 4.5 nM measured by reversal of forskolin (FK)-stimulated inhibition of cAMP production by neuropeptide Y. Pharmacological profiling showed that BMS-193885 has no appreciable affinity at the other neuropeptide Y receptors, and is also 200-fold less potent at the alpha 2 adrenergic receptor. Testing the compound in a panel of 70 G-protein coupled receptors and ion channels resulted in at least 200-fold or greater selectivity, with the exception of the sigma 1 receptor, where the selectivity was 100-fold. When administered intracerebroventricularly or directly into the paraventricular nucleus of the hypothalamus, it blocked neuropeptide Y-induced food intake in rats. Intraperitoneal administration of BMS-193885 (10 mg/kg) also reduced one-hour neuropeptide Y-induced food intake in satiated rats, as well as spontaneous overnight food consumption. Chronic administration of BMS-193885 (10 mg/kg) i.p. for 44 days significantly reduced food intake and the rate of body weight gain compared to vehicle treated control without developing tolerance or affecting water intake. These results provide supporting evidence that BMS-193885 reduces food intake and body weight via inhibition of the central neuropeptide Y1 receptor. BMS-193885 has no significant effect of locomotor activity up to 20 mg/kg dose after 1 h of treatment. It also showed no activity in the elevated plus maze when tested after i.p. and i.c.v. administration, indicating that reduction of food intake is unrelated to anxious behavior. BMS-193885 has good systemic bioavailability and brain penetration, but lacks oral bioavailability. The compound had no serious cardiovascular adverse effect in rats and dogs up to 30 and 10 mg/kg dose, respectively, when dosed intravenously. These data demonstrate that BMS-193885 is a potent, selective, brain penetrant Y1 receptor antagonist that reduces food intake and body weight in animal models of obesity both after acute and chronic administration. Taken together the data suggest that a potent and selective neuropeptide Y1 receptor antagonist might be an efficacious treatment for obesity in humans.


PMID: 18573246

DOI: 10.1016/j.ejphar.2008.06.032

Other references

Svoboda, M.; Fiala, J., 1967: Bilivistan (Schering) and its effect of the osmotic resistance and hemolysis of erythrocytes. Ceskoslovenska Radiologie 21(6): 415-416

Ismail, F.M.D.; Levitsky, D.O.; Dembitsky, V.M., 2009: Aziridine alkaloids as potential therapeutic agents. The present review describes research on natural aziridine alkaloids isolated from both terrestrial and marine species, as well as their lipophilic semi-synthetic, and/or synthetic analogs. Over 130 biologically active aziridine-containing compoun...

Leblanc, R.M.; Boussaad, S.; Tazi, A.; Shao, L.; Tao, N.J., 1997: Photoelectric and surface properties of photosynthetic pigments in 2 D. Biophysical Journal 72(2 PART 2): A125

Yelverton, W., 1991: Phosphogypsum use reduction. Proceedings of the annual meeting Fertilizer Industry Round Table: 1st) 97-98

Kronborg, O.; Christensen, K.; Zimmermann-Nielsen, C., 1985: Chronic pilonidal disease: a randomized trial with a complete 3-year follow-up. Three treatments for chronic pilonidal disease were compared in a randomized trial. Healing without formation of new sinuses occurred equally frequent after excision (E), excision with suture (E + S) and excision with suture under cover with clind...

Stahl, A.; Lagrèze, W.A.; Agostini, H.T., 2013: Pathogenesis of retinopathy of prematurity. Retinopathy of prematurity (ROP) is a complex disease with a multifactorial pathogenetic cascade that is still only partially understood. Important pathogenetic factors are gestational age at birth and birth weight. Potent postnatal factors are ex...

Saxena, Rajiv, 1998: Geckos as food of magpie robin. Journal of the Bombay Natural History Society 95(2): 347, Aug

Mishkin, G.J.; Bosch, J.P.; Velasquez, M.T.; Barlee, V.; Von Albertini, B., 1996: Quantification of dry weight by continuous hematocrit monitoring in hemodialysis patients. Journal of the American Society of Nephrology 7(9): 1522

Brouillette, W.J.; Muccio, D.; Jedrzejas, M.J.; Brouillette, C.G.; Devedjiev, Y.; Cristofoli, W.; Delucas, L.J.; Garcia, J.G.briel; Schmitt, L.; Velu, S.E., 2002: Inhibitors of bacterial NAD synthetase. The present invention provides methods of synthesizing and screening inhibitors of bacterial NAD synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial NAD synthetase enzyme.

Anderson, C.J.; Hoare, S.F.; Ashcroft, M.; Bilsland, A.E.; Keith, W.N., 2005: Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms. Basal telomerase activity is dependent on expression of the hTERT and hTR genes and upregulation of telomerase gene expression is associated with tumour development. It is therefore possible that signal transduction pathways involved in tumour dev...